Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in ...

While the condition can impact quality of life and mental health, seeking treatment and support can make a powerful ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of artificial intelligence (AI)-based solutions for skin is excited to announce the publication of a case study highlighting the use of ...

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

Pfizer showcased new treatments for atopic dermatitis, the leading type of eczema, at the 7th China International Import Expo ...

The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...

The South San Francisco, Calif., biopharmaceutical company in May shut down two trials of zelnecirnon, which was being evaluated as a treatment for asthma and atopic dermatitis.

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

In the world of microbes, the evolution of resistance to antimicrobial drugs is a process that is nearly inevitable. (1) ...

PHAT is a facial rejuvenation therapy that combines nanofat and its stem cells with PRP for anti-aging that lasts for more ...